Strata Critical Medical, Inc. (SRTA)
NASDAQ:SRTA
Want to see SRTA full AI Analyst Report?
Top Page
Strata Critical Medical
(NASDAQ:SRTA)
Select Model
Select Model
Rating:68Neutral
Price Target:
$6.50
▲(42.23% Upside)
Action:Reiterated
Date:06/16/26
The score is mainly capped by weak cash-flow quality and ongoing operating losses in the financial statements despite a strong, low-leverage balance sheet. Offsetting this are constructive technicals (price above major moving averages), a relatively low P/E valuation, and a positive earnings-call backdrop with reiterated guidance and strong year-over-year growth, tempered by sequential margin/mix volatility.
Positive Factors
Strong, low‑leverage balance sheet
Extremely low leverage and meaningful equity provide durable financial flexibility, lowering default risk and enabling funding for operations, fleet and M&A without immediate external capital. This balance-sheet strength cushions cash burn and supports multi-quarter execution.
Negative Factors
Persistent negative operating and free cash flow
Material and persistent cash burn undermines earnings quality and forces dependence on balance-sheet liquidity, ABL capacity or external financing. Even with recent net income, negative operating/free cash flow raises risk to funding aircraft, hub expansion and M&A over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong, low‑leverage balance sheet
Extremely low leverage and meaningful equity provide durable financial flexibility, lowering default risk and enabling funding for operations, fleet and M&A without immediate external capital. This balance-sheet strength cushions cash burn and supports multi-quarter execution.
Read all positive factors
Strata Critical Medical (SRTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$463.78M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)2.09
Revenue Growth1.11%
EPS Growth65.80%
CountryUS
Employees310
SectorHealthcare
Sector Strength45
IndustryAirlines, Airports & Air Services
Share Statistics
EPS (TTM)-0.16
Shares Outstanding86,526,570
10 Day Avg. Volume1,519,011
30 Day Avg. Volume1,202,214
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.62
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.76
Enterprise Value/Gross Profit8.10
Enterprise Value/Ebitda-33.82
Forecast
1Y Price Target
$9.75Price Target Upside113.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$272.93M
Strata Critical Medical Business Overview & Revenue Model
Company Description
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of ...
Strata Critical Medical Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive tone driven by very strong year-over-year revenue (+87.4%), doubled gross profit, rapid build-out and commercial traction in the Clinical business, healthy cash on hand and an active M&A pipeline. Offsetting these positives were sequential softness in Logistics revenue and margins (customer mix and weather-related disruptions), a sequential decline in adjusted EBITDA margin, some one-time cash timing effects, and ongoing uncertainty in donor volumes. Management reiterated full-year guidance and highlighted balance sheet capacity, suggesting confidence in execution despite near-term noise.Positive Updates
Revenue Growth
Total revenue increased 87.4% year-over-year to $67.4M in Q1 2026 (from $35.9M) and was up ~1% sequentially versus Q4 2025; performance was reported as ahead of guidance for both revenue and adjusted EBITDA.
Negative Updates
Sequential Logistics Softness and Margin Pressure
Logistics revenue fell 3.3% sequentially versus Q4 2025 and Logistics gross margin declined to 19.3% (down 30 bps year-over-year and down 220 bps sequentially), driven by a quarter-to-quarter customer mix shift toward OPOs with shorter trip distances.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total revenue increased 87.4% year-over-year to $67.4M in Q1 2026 (from $35.9M) and was up ~1% sequentially versus Q4 2025; performance was reported as ahead of guidance for both revenue and adjusted EBITDA.
Read all positive updates
Company Guidance
The company reiterated full-year 2026 guidance of revenue $260–$275M, adjusted EBITDA $29–$33M and free cash flow before aircraft/engine purchases $15–$22M, noting revenue is trending above the midpoint (partly due to higher fuel surcharges) and Logistics gross margins are expected to remain in the ~20% range while Clinical gross margins are trending above expectations (Q1 Clinical GM ~25%); for Q2 they expect revenue to rise low-single-digits sequentially and adjusted EBITDA margin to be ~10%. Q1 2026 metrics: total revenue $67.4M (+87.4% YoY), Logistics revenue $47.6M (+32.4% YoY), Clinical revenue $19.8M (+12.7% sequential), gross profit $14.1M (GM 21.0%), Logistics gross margin 19.3%, Clinical gross margin 25.0%, adjusted EBITDA $6.4M (9.5% margin), adjusted SG&A $9.2M, operating cash flow $3.9M, free cash flow before aircraft acquisitions $2.1M, capex $5.5M (including $3.7M for 1 aircraft). Balance sheet and capital items called out: cash and short-term investments $58.8M, undrawn ABL $30M (potentially upsizable to $50M), expected Joby earn-out ~ $45M (up to $17.5M due in Aug), 14M warrants expiring at $11.50, Ohio Valley acquisition ~ $1M adding ~ $100k adjusted EBITDA for the rest of 2026, 10 owned aircraft (dedicated fleet ~35) and roughly 20 logistics hubs.Strata Critical Medical Financial Statement Overview
Summary
Income Statement
61
Positive
Balance Sheet
82
Very Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 254.27M | 197.14M | 248.69M | 225.18M | 146.12M | 50.53M |
| Gross Profit | 55.14M | 41.13M | 58.92M | 42.12M | 22.27M | 10.52M |
| EBITDA | -13.21M | -14.17M | -21.60M | -50.43M | -22.31M | -43.10M |
| Net Income | 46.99M | 41.35M | -27.31M | -56.08M | -27.26M | -40.05M |
Balance Sheet | ||||||
| Total Assets | 327.62M | 325.47M | 256.68M | 294.94M | 325.02M | 335.88M |
| Cash, Cash Equivalents and Short-Term Investments | 58.79M | 61.23M | 127.14M | 166.14M | 192.08M | 281.97M |
| Total Debt | 4.47M | 3.31M | 9.32M | 24.52M | 18.33M | 716.00K |
| Total Liabilities | 41.89M | 46.40M | 34.74M | 60.64M | 50.54M | 44.51M |
| Stockholders Equity | 285.73M | 279.07M | 221.94M | 234.30M | 274.49M | 291.37M |
Cash Flow | ||||||
| Free Cash Flow | -53.00M | -59.92M | -35.51M | -34.46M | -37.86M | -16.42M |
| Operating Cash Flow | -39.66M | -48.91M | -2.52M | -32.35M | -37.13M | -15.62M |
| Investing Cash Flow | 74.07M | 69.75M | -1.02M | 17.09M | 79.34M | -321.34M |
| Financing Cash Flow | -10.65M | -8.91M | -5.76M | -76.00K | -1.08M | 332.26M |
Strata Critical Medical Technical Analysis
Neutral
4.57
Price Trends
5.46
Negative
4.94
Positive
4.97
Positive
Market Momentum
<0.01
Positive
42.12
Neutral
18.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTA, the sentiment is Neutral. The current price of 4.57 is below the 20-day moving average (MA) of 5.84, below the 50-day MA of 5.46, and below the 200-day MA of 4.97, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 42.12 is Neutral, neither overbought nor oversold. The STOCH value of 18.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SRTA.
Strata Critical Medical Risk Analysis
Strata Critical Medical disclosed 57 risk factors in its most recent earnings report. Strata Critical Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Strata Critical Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $463.78M | -32.82 | 18.97% | ― | 1.11% | 65.80% | |
57 Neutral | $304.78M | 25.96 | 2.83% | ― | 6.19% | ― | |
54 Neutral | $183.43M | -1.87 | 6.87% | ― | 14.51% | 28.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $91.38M | -0.17 | 140.66% | ― | -3.24% | 35.57% |
* Healthcare Sector Average
SRTA
Strata Critical Medical
5.36
1.23
29.78%
ASLE
AerSale Corporation
6.45
0.37
6.09%
FLYX
flyExclusive
1.91
-0.29
-13.18%
SRFM
Surf Air Mobility, Inc.
0.91
-2.36
-72.17%
Strata Critical Medical Corporate Events
Executive/Board ChangesShareholder Meetings
Strata Critical Medical shareholders back directors and governance items
Positive
Jun 3, 2026
On May 28, 2026, Strata Critical Medical, Inc. held its annual meeting of stockholders, where investors elected two Class II directors, William A. Heyburn and Andrew Lauck, to serve on the board until the 2029 annual meeting. The voting results sh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.